Title : Small-molecule inhibitors of carboxylesterase Notum - Zhao_2021_Future.Med.Chem__ |
Author(s) : Zhao Y , Jolly S , Benvegnu S , Jones EY , Fish PV |
Ref : Future Med Chem , : , 2021 |
Abstract :
Notum has recently been identified as a negative regulator of Wnt signaling through the removal of an essential palmitoleate group from Wnt proteins. There are emerging reports that Notum plays a role in human disease, with published data suggesting that targeting Notum could represent a new therapeutic approach for treating cancer, osteoporosis and neurodegenerative disorders. Complementary hit-finding strategies have been applied with successful approaches that include high-throughput screening, activity-based protein profiling, screening of fragment libraries and virtual screening campaigns. Structural studies are accelerating the discovery of new inhibitors of Notum. Three fit-for-purpose examples are LP-922056, ABC99 and ARUK3001185. The application of these small-molecule inhibitors is helping to further advance an understanding of the role Notum plays in human disease. |
PubMedSearch : Zhao_2021_Future.Med.Chem__ |
PubMedID: 33882714 |
Gene_locus related to this paper: human-NOTUM |
Inhibitor | 4F-329S LP-914822 N-[2-(5-fluoro-1H-indol-3-yl)ethyl]acetamide JVB CHEMBL4539054 LP-922056 LP-935001 ARUK3001185 ABC99 |
Gene_locus | human-NOTUM |
Family | Pectinacetylesterase-Notum |
Zhao Y, Jolly S, Benvegnu S, Jones EY, Fish PV (2021)
Small-molecule inhibitors of carboxylesterase Notum
Future Med Chem
:
Zhao Y, Jolly S, Benvegnu S, Jones EY, Fish PV (2021)
Future Med Chem
: